Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View National Institute on Child Health and Human Development (NICHD); Opportunity for Cooperative Research and Development Agreement Interested parties should notify this office in writing of their intent to file a formal proposal no later than April 11, 2001. Formal proposals must be submitted to this office no later than May 11, 2001.
View Centers for Disease Control and Prevention
View Prospective Grant of Co-Exclusive License: Homogeneous Tests for Sequentially Determining Lipoprotein Fractions Only written comments and/or applications for a license which are received by he NIH Office of Technology Transfer on or before April 27, 2001 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Method and Apparatus for Constructing Tissue Microarrays Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 23, 2001 will be considered.
View Government-Owned Inventions; Availability for Licensing
View National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Opportunity for Cooperative Research and Development Agreements (CRADAs) to Develop Monoclonal Antibodies and/or Other Reagents and Products for Use in Identifying the Dombrock Blood Group Carrier Molecule Aimed at Improving Blood Typing Practices Through Molecular Means Only written CRADA capability statements received by the NIDDK on or before March 30, 2001 will be considered during the initial design phase; confidential information must be clearly labeled. Potential Collaborators may be invited to meet with the Selection Committee at the Collaborator's expense to provide additional information. The Institute may issue an additional notice of CRADA opportunity during the design phase.
View Prospective Grant of Exclusive License: Method for Preparing 17α-Acetoxy-11β-(4-,N-Dimethylaminophyl)-19-Norpregna-4, 9-Diene-3,20-Dione, Intermediates Useful in the Method, and Methods for the Preparation of Such Intermediates Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 18, 2001 will be considered.
View Prospective Grant of Exclusive License: Orally Active Derivatives of 1,3,5(10)-Estratriene Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 19, 2001 will be considered.
View Prospective Grant of Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas Aeruginosa, Chlamydia, Trachomatis and Mycoplasma Pneumonia Only written comments and/or applications for a license which are received by NIH on or before March 19, 2001 will be considered.
View National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Identification and Development of Chemical Compounds That Interact With the Polo-Box of Polo Kinases, as Potential Therapeutic Targets for the Inhibition of Cellular Proliferation Interested parties should notify this office in writing of their interest in filing a formal proposal on or before March 12, 2001. Potential CRADA Collaborators will then have until on or before April 11, 2001 to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View Prospective Grant of Exclusive License: Hydroxylamine Compositions for the Prevention or Retardation of Cataracts Only written comments and/or application for a license which is received by the NIH Office of Technology Transfer on or before February 26, 2001, will be considered.
View Prospective Grant of Exclusive License: Treatment of Retroviral Infections With a Phorbol Ester Derivative Only written comments and/or license applications which are received by the NIH Office of Technology Transfer on or before February 20, 2001 will be considered.
View Prospective Grant of Exclusive License: Compositions and Methods for the Stimulation of Proliferation and Differentiation of Pancreatic Cells Ex Vivo Only written comments and/or applications for a license which are received by NIH on or before February 5, 2001, will be considered.
View Prospective Grant of Exclusive License: Methods and Compositions for the Detection and Treatment of Insulin Dependent Diabetes Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 5, 2001 will be considered.
View Government-Owned Inventions; Availability for Licensing
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) Collaboration in the Identification, Characterization and Development of Inhibitors of the Smad3 Signaling Protein for Use in the Treatment of Wounds and Fibrotic Diseases Characterized by Chronic Inflammation Interested parties should notify this office in writing of their interest in filing a formal proposal no later than January 22, 2001. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Identification and Development of Chemical Compounds That Interact With the Polo-Box of Polo Kinases, as Potential Therapeutic Targets for the Inhibition of Cellular Proliferation Interested parties should notify this office in writing of their interest in filing a formal proposal no later than January 2, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Insulin Producing Cells Differentiated From Non-Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof; Correction
View Prospective Grant of Exclusive License: Insulin Producing Cells Differentiated from Non-Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 18, 2000 will be considered.
View Prospective Grant of an Exclusive License: Treatment of Gaucher Disease Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 20, 2000 will be considered.
View National Cancer Institute: Development of a Method for High Speed Parallel Nucleic Acid Sequencing Organizations must submit a proposal summary of one page or less, to NCI on or before November 13, 2000. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest.
View National Cancer Institute: Development of Molecular Computing Devices. Organizations must submit a proposal summary, of one page or less, to NCI. Proposal review by NCI will begin on or before October 16, 2000. However, proposals will be accepted until appropriate collaborator(s) are found. Guidelines for preparing full CRADA proposals will be communicated to all respondents with whom initial discussions will have established sufficient mutual interest.
View National Cancer Institute: Development of a Molecular Rotation Engine Organizations must submit a proposal summary of one page or less, to NCI on or before November 13, 2000. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest.